Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

Alissa A. Thomas, Lauren E. Abrey, Robert Terziev, Jeffrey Raizer, Nina L. Martinez, Peter Forsyth, Nina Paleologos, Matthew Matasar, Craig S. Sauter, Craig Moskowitz, Stephen D Nimer, Lisa M. Deangelis, Thomas Kaley, Sean Grimm, David N. Louis, J. Gregory Cairncross, Katherine S. Panageas, Samuel Briggs, Geraldine Faivre, Nimish A. MohileJayesh Mehta, Philip Jonsson, Debyani Chakravarty, Jianjiong Gao, Nikolaus Schultz, Cameron W. Brennan, Jason T. Huse, Antonio Omuro

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background. Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) as a potential strategy to defer radiotherapy. Methods. Patients with AO/AOA received 6 cycles of TMZ (200 mg/m2 × 5/28 day). Responding patients were eligible for HDC (thiotepa 250 mg/m2/day

Original languageEnglish (US)
Pages (from-to)1380-1390
Number of pages11
JournalNeuro-Oncology
Volume19
Issue number10
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Keywords

  • 1p/19q codeletion
  • Anaplastic oligodendroglioma
  • Autologous stem cell transplant
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma'. Together they form a unique fingerprint.

  • Cite this

    Thomas, A. A., Abrey, L. E., Terziev, R., Raizer, J., Martinez, N. L., Forsyth, P., Paleologos, N., Matasar, M., Sauter, C. S., Moskowitz, C., Nimer, S. D., Deangelis, L. M., Kaley, T., Grimm, S., Louis, D. N., Cairncross, J. G., Panageas, K. S., Briggs, S., Faivre, G., ... Omuro, A. (2017). Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-Oncology, 19(10), 1380-1390. https://doi.org/10.1093/neuonc/nox086